Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06115135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06115135 · ClinicalTrials.gov record · last posted 2025-01-16

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 2
Started2024-06-20
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 16, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2023-10-30; most recent amendment 2025-01-14. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-01-14
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT06115135
Lead Sponsor Oncotherapeutics
Conditions Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Enrollment 39 participants
Start Date 2024-06-20
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-16